))
Delcath Systems: Filtering Through Its Past & Future
Manage episode 337249292 series 3380517
Content provided by Encode Ideas, L.P., Encode Ideas, and L.P.. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Encode Ideas, L.P., Encode Ideas, and L.P. or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
An interview with Gerard Michel, CEO of Delcath Systems, where Gerard reflects back on his time with Vericel, the decision to become CEO of Delcath, the initial NDA submission for the HEPZATO™ KIT, and the preliminary data release from the Phase 3 FOCUS study. Gerard also addresses the future for Delcath, including the impending full Phase 3 FOCUS results, future clinical indications to be pursued with the HEPZATO™ KIT, and commercial dynamics in the interventional oncology space.
Companies discussed during the podcast:
Delcath Systems, Inc (Nasdaq: DCTH)
Vericel Corporation (Nasdaq: VCEL)
Immunocore Ltd (Nasdaq: IMCR)
Bright Minds Biosciences (OTCQB: BMBIF, CSE: DRUG)
Gerard Michel, CEO of Delcath Systems, Inc. (“Delcath”) appeared on this episode of the podcast. Listeners are urged to review Delcath’s SEC filings and cautioned not to place undue reliance on any forward-looking statements. Delcath undertakes no obligation to update forward-looking statements if circumstances or management’s estimates or opinions should change except as required by applicable securities laws.
7 episodes
Share
